Sandeep Bodduluri1,2,3, Abhilash Kizhakke Puliyakote4, Arie Nakhmani1,5, Jean-Paul Charbonnier6, Joseph M Reinhardt7, Surya P Bhatt1,2,3. 1. UAB Lung Imaging Core. 2. UAB Lung Health Center. 3. Division of Pulmonary, Allergy and Critical Care Medicine, and. 4. Department of Electrical and Computer Engineering, University of Alabama at Birmingham, Birmingham, Alabama. 5. Department of Radiology, University of California, San Diego, La Jolla, California. 6. Thirona, Nijmegen, the Netherlands; and. 7. Department of Biomedical Engineering, University of Iowa, Iowa City, Iowa.
Abstract
Rationale: Airway remodeling in chronic obstructive pulmonary disease (COPD) is due to luminal narrowing and/or loss of airways. Existing computed tomographic metrics of airway disease reflect only components of these processes. With progressive airway narrowing, the ratio of the airway luminal surface area to volume (SA/V) should increase, and with predominant airway loss, SA/V should decrease. Objectives: To phenotype airway remodeling in COPD. Methods: We analyzed the airway trees of 4,325 subjects with COPD Global Initiative for Chronic Obstructive Lung Disease stages 0 to 4 and 73 nonsmokers enrolled in the multicenter COPDGene (Genetic Epidemiology of COPD) cohort. Surface area and volume measurements were estimated for the subtracheal airway tree to derive SA/V. We performed multivariable regression analyses to test associations between SA/V and lung function, 6-minute-walk distance, St. George's Respiratory Questionnaire, change in FEV1, and mortality, adjusting for demographics, total airway count, airway wall thickness, and emphysema. On the basis of the change in SA/V over 5 years, we categorized subjects into predominant airway narrowing [positive ∆(SA/V) more than 0] and predominant airway loss [negative ∆(SA/V) less than 0] and compared survival between the two groups.Measurements and Main Results: Airway SA/V was independently associated with FEV1/FVC (β = 0.12; 95% confidence interval [CI], 0.09-0.14; P < 0.001) and FEV1% predicted (β = 20.10; 95% CI, 15.13-25.08; P < 0.001). Airway SA/V was also independently associated with 6-minute-walk distance, respiratory quality of life, and lung function decline. Compared with subjects with predominant airway narrowing (n = 2,914; 66.3%), those with predominant airway loss (n = 1,484; 33.7%) had worse survival (adjusted hazard ratio for all-cause mortality = 1.58; 95% CI, 1.18-2.13; P = 0.002).Conclusions: Computed tomography-based airway SA/V is an imaging biomarker of airway remodeling and provides differential information on predominant airway narrowing and loss in COPD. SA/V is associated with respiratory morbidity, lung function decline, and survival.
Rationale: Airway remodeling in chronic obstructive pulmonary disease (COPD) is due to luminal narrowing and/or loss of airways. Existing computed tomographic metrics of airway disease reflect only components of these processes. With progressive airway narrowing, the ratio of the airway luminal surface area to volume (SA/V) should increase, and with predominant airway loss, SA/V should decrease. Objectives: To phenotype airway remodeling in COPD. Methods: We analyzed the airway trees of 4,325 subjects with COPD Global Initiative for Chronic Obstructive Lung Disease stages 0 to 4 and 73 nonsmokers enrolled in the multicenter COPDGene (Genetic Epidemiology of COPD) cohort. Surface area and volume measurements were estimated for the subtracheal airway tree to derive SA/V. We performed multivariable regression analyses to test associations between SA/V and lung function, 6-minute-walk distance, St. George's Respiratory Questionnaire, change in FEV1, and mortality, adjusting for demographics, total airway count, airway wall thickness, and emphysema. On the basis of the change in SA/V over 5 years, we categorized subjects into predominant airway narrowing [positive ∆(SA/V) more than 0] and predominant airway loss [negative ∆(SA/V) less than 0] and compared survival between the two groups.Measurements and Main Results: Airway SA/V was independently associated with FEV1/FVC (β = 0.12; 95% confidence interval [CI], 0.09-0.14; P < 0.001) and FEV1% predicted (β = 20.10; 95% CI, 15.13-25.08; P < 0.001). Airway SA/V was also independently associated with 6-minute-walk distance, respiratory quality of life, and lung function decline. Compared with subjects with predominant airway narrowing (n = 2,914; 66.3%), those with predominant airway loss (n = 1,484; 33.7%) had worse survival (adjusted hazard ratio for all-cause mortality = 1.58; 95% CI, 1.18-2.13; P = 0.002).Conclusions: Computed tomography-based airway SA/V is an imaging biomarker of airway remodeling and provides differential information on predominant airway narrowing and loss in COPD. SA/V is associated with respiratory morbidity, lung function decline, and survival.
Authors: Thomas B Grydeland; Asger Dirksen; Harvey O Coxson; Tomas M L Eagan; Einar Thorsen; Sreekumar G Pillai; Sanjay Sharma; Geir Egil Eide; Amund Gulsvik; Per S Bakke Journal: Am J Respir Crit Care Med Date: 2009-11-19 Impact factor: 21.405
Authors: John E McDonough; Ren Yuan; Masaru Suzuki; Nazgol Seyednejad; W Mark Elliott; Pablo G Sanchez; Alexander C Wright; Warren B Gefter; Leslie Litzky; Harvey O Coxson; Peter D Paré; Don D Sin; Richard A Pierce; Jason C Woods; Annette M McWilliams; John R Mayo; Stephen C Lam; Joel D Cooper; James C Hogg Journal: N Engl J Med Date: 2011-10-27 Impact factor: 91.245
Authors: Sandeep Bodduluri; Abhilash S Kizhakke Puliyakote; Sarah E Gerard; Joseph M Reinhardt; Eric A Hoffman; John D Newell; Hrudaya P Nath; MeiLan K Han; George R Washko; Raúl San José Estépar; Mark T Dransfield; Surya P Bhatt Journal: J Clin Invest Date: 2018-10-29 Impact factor: 14.808
Authors: Jean-Paul Charbonnier; Esther Pompe; Camille Moore; Stephen Humphries; Bram van Ginneken; Barry Make; Elizabeth Regan; James D Crapo; Eva M van Rikxoort; David A Lynch Journal: Respir Med Date: 2018-11-20 Impact factor: 3.415
Authors: Alejandro A Diaz; Farbod N Rahaghi; James C Ross; Rola Harmouche; Juerg Tschirren; Raul San José Estépar; George R Washko Journal: Respir Res Date: 2015-02-14
Authors: Emily S Wan; Peter J Castaldi; Michael H Cho; John E Hokanson; Elizabeth A Regan; Barry J Make; Terri H Beaty; MeiLan K Han; Jeffrey L Curtis; Douglas Curran-Everett; David A Lynch; Dawn L DeMeo; James D Crapo; Edwin K Silverman Journal: Respir Res Date: 2014-08-06
Authors: Richard Kraemer; Hans-Jürgen Smith; Fabian Gardin; Jürg Barandun; Stefan Minder; Lukas Kern; Martin H Brutsche Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-09-01
Authors: Fernando J Martinez; Alvar Agusti; Bartolome R Celli; MeiLan K Han; James P Allinson; Surya P Bhatt; Peter Calverley; Sanjay H Chotirmall; Badrul Chowdhury; Patrick Darken; Carla A Da Silva; Gavin Donaldson; Paul Dorinsky; Mark Dransfield; Rosa Faner; David M Halpin; Paul Jones; Jerry A Krishnan; Nicholas Locantore; Fernando D Martinez; Hana Mullerova; David Price; Klaus F Rabe; Colin Reisner; Dave Singh; Jørgen Vestbo; Claus F Vogelmeier; Robert A Wise; Ruth Tal-Singer; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2022-02-01 Impact factor: 21.405